Brain Tumor Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Brain Tumor Therapeutics Market is segmented by Type of Brain Cancer (Glioblastoma, Meningioma, Pituitary Tumors, and Other Types of Brain Cancer), Therapy, and Geography.

Market Snapshot

Brain Tumor Therapeutics Market picture 1
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 9.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

Brain tumor therapeutics market is expected to register a notable growth rate of 9.5% over the forecast period. The growth is attributed to the growing burden of brain tumor, raising awareness and increasing R&D on cancer therapeutics. A brain tumour occurs when abnormal cells form within the brain. There are two major types of tumors, malignant or cancerous tumors and benign tumours.

According to the World Cancer Research Fund 2018 statistics, Brain and CNS cancers are account for 1.7% of the total new cancer cases i.e. 296,851 new cases in 2018. The increasing burden of brain cancer across the world is expected to drive the demand in the brain tumor therapeutics market over the forecast period. 

The treatment for brain tumour differs depending on several factors, such as age, general health, and the size, location, and type of tumour.

However, the high cost of cancer therapy and side effects associated with brain tumor therapeutics are projected to hamper the market growth over the forecast period.

Scope of the Report

Brain tumor arises from abnormal growth of cancerous cells in the brain. Brain tumor is one of the leading causes of death, globally. Meningioma is the most common kind of brain tumor and the hardest to treat, while, treatments for glioma usually have better outcomes.

Type of Brain Cancer
Glioblastoma
Meningioma
Pituitary Tumors
Other Types of Brain Cancer
Therapy
Chemotherapy
Immunotherapy
Gene Therapy
Other Therapies
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East & Africa
GCC
South Africa
Rest of Middle-East & Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Immunotherapy Segment is Expected to Register Robust Growth

  • Immunotherapy is the treatment of disease by activating or suppressing the immune system. Vaccines are a promising new form of immunotherapy that stimulates the immune system to fight cancer. 
  • The use of immunotherapy in glioblastoma multiforme, which is the most common primary malignant brain tumor in adults, has been found to be effective. 
  • AstraZeneca's AZD1390 is a highly potent brain penetrant ATM (Ataxia telangiectasia mutant) kinase inhibitor that blocks ATM-dependent signalling and repair of DNA double-strand breaks (DSBs) in the genome. This is user development by the AstraZeneca for the treatment of brain tumours. 
  • Thus, the rising R&D initiatives to develop the immunotherapeutics to treat the brain tumors and continuous support from the government authorities to develop the chance therapeutics are projected to fuel the segment growth over the forecast period.
brain.png

The United States is Expected to Retain the Largest Market Share During the Forecast Period

North America brain tumour market is projected to have significant share over the forecast period. The United States is anticipated to lead the market, this is attributed to the developed healthcare industry, coupled with rising awareness regarding advanced technologies among the population in this region.

According to American Cancer Socity about 23,890 malignant tumors of the brain or spinal cord (13,590 in males and 10,300 in females) will be diagnosed in 2020. Furthermore, the same report stated that about 18,020 people (10,190 males and 7,830 females) will die from brain and spinal cord tumors in 2020. 

Moreover, meningioma is the most common form of brain tumor, followed by gliomas. Eflornithine is designated as an orphan drug in the United States and received the breakthrough therapy designation for the treatment of anaplastic glioma. This is likely to positively impact the growth of the market over the forecast period.

Brain Tumor Therapeutics Market - Growth Rate by Region - Image

Competitive Landscape

The market for brain tumor therapeutics is highly concentrated with a few global players controlling a significant share of the market. Key players in the market include Amgen Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Co, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co. Inc., Novartis AG, and Pfizer Inc., among others.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Incidence of Brain Tumor

      2. 4.2.2 Strong R&D Initiatives from Key Players

      3. 4.2.3 Increasing Government Initiatives for Cancer Awareness

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Cancer Therapies

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 Type of Brain Cancer

      1. 5.1.1 Glioblastoma

      2. 5.1.2 Meningioma

      3. 5.1.3 Pituitary Tumors

      4. 5.1.4 Other Types of Brain Cancer

    2. 5.2 Therapy

      1. 5.2.1 Chemotherapy

      2. 5.2.2 Immunotherapy

      3. 5.2.3 Gene Therapy

      4. 5.2.4 Other Therapies

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East & Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East & Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Amgen Inc.

      2. 6.1.2 AstraZeneca PLC

      3. 6.1.3 Bayer AG

      4. 6.1.4 Bristol-Myers Squibb Co

      5. 6.1.5 Eisai Inc.

      6. 6.1.6 F. Hoffmann-La Roche Ltd

      7. 6.1.7 GlaxoSmithKline PLC

      8. 6.1.8 Johnson & Johnson

      9. 6.1.9 Merck & Co. Inc.

      10. 6.1.10 Novartis AG

      11. 6.1.11 Pfizer Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Brain Tumor Therapeutics Market market is studied from 2018 - 2026.

The Brain Tumor Therapeutics Market is growing at a CAGR of 9.5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Bayer AG, F. Hoffmann-La Roche Ltd, Eisai Inc., Novartis AG, Merck & Co. Inc. are the major companies operating in Brain Tumor Therapeutics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!